While the reiteration of an Outperform rating suggests continued confidence in Zura Bio's potential, the reduction in the price target might reflect adjustments in valuation metrics or market conditions. This mixed signal could lead to neutral short-term price movement as investors digest both the continued endorsement and the tempered valuation expectation.